Client News

Okyo Pharma Limited: Grant of options -PDMR dealing
Home / Client News / Okyo Pharma Limited: Grant of options -PDMR dealing

London, March 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today announces that the board of directors of the Company (the “Board” or “Directors”), acting on a recommendation of the Remuneration Committee has awarded the following options (each to acquire one new ordinary share of no par value) (“Options”) to directors and persons discharging managerial responsibility:

 

Gary S. Jacob

Chief Executive Officer

5,500,000 Options

Keeren Shah

Chief Financial Officer

6,550,000 Options

Dr. Raj Patil

Chief Scientific Officer

15,500,000 Options

Willy Simon

Non-executive director

400,000 Options

John Brancaccio

Non-executive director

1,000,000 Options

Bernard Denoyer

Non-executive director

200,000 Options

 

The exercise price for all options is £0.025 per share. The options all vest in 4 equal tranches over 4 years, with the first tranche vesting on 14 March 2024, and all options have a life of ten years.

 

Holders of the Company’s ADS should note that for the purposes of comparison of the quantum of the awards, each ADS held represents 65 ordinary shares.

 This information set out below is provided in accordance with Article 19(3) of UK MAR:

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Gary S. Jacob

Chief Executive Officer

Keeren Shah

Chief Financial Officer

Dr. Raj Patil

Willy Simon

John Brancaccio

Bernard Denoyer

Chief Scientific Officer

Non-executive director

Non-executive director

Non-executive director

2

Reason for the notification

a)

Position/status

See 1a) above

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

OKYO Pharma Limited

b)

LEI

213800VVN5CB56Y15A05

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares of no par value

b)

Identification code

ISIN for OKYO Pharma Limited: GG00BD3FV870

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price: £0.025 per share

Volumes:

Gary S. Jacob

5,500,000

Keeren Shah

6,550,000

Dr. Raj Patil

Willy Simon

John Brancaccio

Bernard Denoyer

15,500,000

400,000

1,000,000

200,000

e)

Aggregated information

– Aggregated volume

– Price

n/a

f)

Date of the transaction

14 March 2023

g)

Place of the transaction

Outside of a trading venue

 

Director/PDMR Dealings – 07:01:01 15 Mar 2023 – OKYO News article | London Stock Exchange

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This